Search for content, post, videos

Hey there Peter Zerhouni, CEO, InDex Pharmaceuticals

Peter Zerhouni Photo Kristian Pohl
InDex Pharmaceuticals recently announced conclusions from its CONDUCT study, evaluating their TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. Congratulations to the positive results from the CONDUCT study. What are the next steps and when can we expect additio
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.